Browsing Tag
CARVYKTI
4 posts
NYSE: JNJ Q4 earnings rise 49% to $2.10 EPS; oncology and neuroscience lead portfolio momentum
Johnson & Johnson posts $94.2B in 2025 revenue and sets $100.5B FY26 target. Find out what’s driving growth and how STELARA’s erosion could impact momentum.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.
Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase…
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA)…